Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures

Heart

Volumn 93, Issue 6, 2007, Pages 698-702

  Onbasili, Alper O ^a   Yeniceriglu, Yavuz ^a   Agaoglu, Pinar ^a   Karul, Aslihan ^a   Tekten, Tarkan ^a   Akar, Harun ^a   Discigil, Guzel ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; CREATININE; IOPROMIDE; PLACEBO; SODIUM CHLORIDE; TRIMETAZIDINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; VENOUS BLOOD;

ADMINISTRATION, ORAL; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HEART CATHETERIZATION; HUMANS; IOHEXOL; ISOTONIC SOLUTIONS; KIDNEY DISEASES; MALE; MIDDLE AGED; PREMEDICATION; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SODIUM CHLORIDE; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 34249334681     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.097477     Document Type: Article

References (55)

1. Murphy SW, Barrent BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11:177-82.
2. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75.
3. Gruberg I, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 hours of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542-8.
4. Tomasso C. Contrast induced nephrotoxicity in patients undergoing cardiac catheterization. Cathet Cardiovasc Diagn 1994;31:316-21.
5. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:143-9.
6. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The lohexol Cooperative Study. Kidney Int 1995;47:254-61.
7. Oldemeyer JB, Biddle WP, Wurdeman RL, et al. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 2003;146:E23.
8. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-64.
9. Iakovou I, Dangas G, Mehran R, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003;15:18-22.
10. Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989;320:149-53.
11. Baliga R, Udea N, Walker PD, et al. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997;29:465-77.
12. Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990;258:115-20.
13. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast-induced renal injury in volume depletion. Kidney Int 1992;41:1008-15.
14. Garni AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc 2004;79:211-19.
15. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20.
16. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 1999;33:403-11.
17. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999;83:260-3, A5.
18. Mueller C, Buerkle G, Buettner HI, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-36.
19. Harpey C, Clauser P, Labrid C, et al. Trimetazidine, a cellular antiischemic agent. Cardiovasc Drug Rev 1989;6:292-312.
20. Elimadi A, Settaf A, Morin D, et al. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. J Pharmacol Exp Ther 1998;286:23-8.
21. Aubert A, Bernard C, Clauser P, et al. Effect of pnenazine methosulfate on electrophysiological activity of the semisircular canal: antioxidant properties of trimetazidine. Eur J Pharmacol 1989;174:215-25.
22. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8.
23. Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987;286:97-110.
24. Singh D, Chopra K. Effect of trimetazidine on renal ischemia/reperfusion injury in rats. Pharmacol Res 2004;50:623-9.
25. Zoppo A, Faggiotto A, Redaelli L, et al. Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. Transplantation 1999;68:1211.
26. Hauet T, Baumert H, Amor B, et al. Pharmacological limitation of damage to renal medulla after cold storage and transplantation by trimetazidine. J Pharmacol Exp Ther 2000;292:254-60.
27. Singh D, Chander V, Chopra K. Carvedilol and trimetazidine attenuates ferric nitrilotriacetate induced oxidative renal injury in rats. Toxicology 2003;191:143-51.
28. Cockcroft DW, Gault MH. Prediction of creatinin clearance from serum creatinin. Nephron 1976;16:31-41.
29. Tepel M, Van Der Giet M, Schwarzfeld C, et al. Prevention of radiocontrast agent induced conductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
30. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med 1989;110:119- 24.
31. Kumar S, Hull JD, Lathi S, et al. Low incidence of renal failure after angiography. Arch Intern Med 1981;141:1268-70.
32. Hizoh I, Haller C. Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress. Invest Radiol 2002;37:428-34.
33. Katholi RE, Woods WT Jr, Taylor GJ, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998;32:64-71.
34. Idee JM, Lancelot E, Berthommier C, et al. Effects of non-ionic monomeric and dimeric iodinated contrast media on renal and systemic haemodynamics in rats. Fundam Clin Pharmacol 2000;14:11-18.
35. Heyman SN, Rosenberger C, Rosen S. Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy. Nephrol Dial Transplant 2005;20(Suppl 1):i6-11.
36. Liss P, Nygren A, Erikson U, et al. Injection of low and iso-osmolar contrast medium decreases oxygen tension in the renal medulla. Kidney Int 1998;53:698-702.
37. Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990;11:7-12.
38. Noble MIM, Belchr PR, Drake-Holland AJ. Limitation of infarct size by trimetazidine in the rabbit. Am J Cardiol 1995;76:41-4.
39. Grekas D, Dioudis C, Papageorgiou G, et al. Lipid peroxidation after acute renal ischemia and reperfusion in rats: the effect of trimetazidine. Ren Fail 1996;18:545-52.
40. Özden A, Aybek Z, Scrydam N, et al. Cytoprotective effect of trimetazidine on 75 min warm renal iscnemia-reperfusion injury in rats. Eur Surg Res 1998;30:227-34.
41. Tsimoyiannis EC, Moutesidou KJ, Moschos CM, et al. Trimetazidine for prevention of hepatic injury induced by ischemia and reperfusion in rats. Eur J Surg 1993;159:89-93.
42. Bailey SR. Past and present attempts to prevent radiocontrast nephropathy. Rev Cardiovasc Med 2001;2:s14-18.
43. Boccalandro F, Amhad M, Smalling RW, et al. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003;58:336-41.
44. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-83.
45. Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003;41:2114-18.
46. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.
47. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-8.
48. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289:553-8.
49. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-8.
50. Yeniceroglu Y, Yilmaz O, Sarioglu S, et al. Effects of N-acetyl cystein on radiocontrast nephropathy in rats. Scand J Urol Nephrol 2006;40:63-9.
51. Safirstein R, Andrade L, Vieria JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents: a new use for an old drug. N Engl J Med 2000;343:210-11.
52. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent nephropathy by hemofiltration. N Engl J Med 2003;349:1333-40.
53. Sterner G, Frennby B, Kurkus J, et al. Does post-angiographic hemodialysis reduce the risk of contrast-medium nephropathy. Scand J Urol Nephrol 2000;34:323-6.
54. Lehnert T, Keller E, Gondolf K, et al. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 1998;13:358-62.
55. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:2328-34.